ARTES Biotechnology GmbH and NL Biotechnologies LLC join in a strategic collaboration and co-marketing alliance
The first product that is available right from the start is a Hansenula polymorpha derived Hepatitis E vaccine. Proof-of-principle and animal studies (mice and macaques) have been done and shown very good result and high immune answers.
“The Hepatitis E transmission is a person-to-person one, normally triggered to the fecal-oral route. Infections occur because of consumption of contaminated water and ingestion of raw or uncooked food – therefore it is a disease most common in developing countries,“ Vitaly Granovskiy, managing director of NL Biotechnologies carried out.
And Dr. Michael Piontek, managing director of ARTES added, ”With the Hepatitis E process we have another reliable and cost-efficient VLP-based production process in our portfolio. Like for HepB and avian flu, the manufacturing costs for this vaccine are low because of the effective technology behind. In our mind, it should be an interesting process particular for developing countries. “
The partners are now looking for companies to out-license the process.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.